The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review.

Détails

ID Serval
serval:BIB_4307E0AEBAAC
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
The role of [18F]FDG PET/CT in paraneoplastic autoimmune disorders: an umbrella review.
Périodique
The quarterly journal of nuclear medicine and molecular imaging
Auteur⸱e⸱s
Muoio B., Albano D., Dondi F., Bertagna F., Annunziata S., Fiz F., Piccardo A., Sadeghi R., Treglia G.
ISSN
1827-1936 (Electronic)
ISSN-L
1824-4785
Statut éditorial
Publié
Date de publication
09/2022
Peer-reviewed
Oui
Volume
66
Numéro
3
Pages
229-233
Langue
anglais
Notes
Publication types: Journal Article ; Meta-Analysis
Publication Status: ppublish
Résumé
Paraneoplastic autoimmune disorders (PAD) are a group of autoimmune diseases associated with neoplasms. Several evidence-based articles (systematic reviews and meta-analyses) have reported data about the role of positron emission tomography (PET) and related hybrid modalities (e.g., PET/CT) using 2-deoxy-2-[18F]fluoro-D-glucose ([ <sup>18</sup> F]FDG) in patients with PAD. We performed an umbrella review of published systematic reviews and meta-analyses in this setting to provide an evidence-based summary and suggestions for further studies. Several databases were searched to find systematic reviews and meta-analysis on [ <sup>18</sup> F]FDG PET/CT in PAD. Evidence-based data support the use of [ <sup>18</sup> F]FDG PET/CT in patients with suspected PAD for investigating an underlying malignancy even if it is still unclear whether [ <sup>18</sup> F]FDG PET/CT should be performed after negative/inconclusive conventional imaging or as part of the initial workup of PAD.
Mots-clé
Autoimmune Diseases/diagnostic imaging, Fluorodeoxyglucose F18, Humans, Neoplasms, Positron Emission Tomography Computed Tomography, Positron-Emission Tomography/methods
Pubmed
Création de la notice
31/05/2022 10:47
Dernière modification de la notice
14/06/2023 6:56
Données d'usage